Results 141 to 150 of about 29,631 (205)

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

Summary CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a
Ascaso del Río, Ana, Pérez Ingidua, Carla, García Pérez, Javier, Portolés Pérez, Antonio, Lora Pablos, David, Díez Fuertes, Francisco, Gómez De La Cámara, Agustín Ramón   +6 more
core   +1 more source

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial

Infectious Diseases and Therapy
Introduction COVID-19 continues to cause substantial health burden, particularly among vulnerable populations. Vaccines remain a vital tool in preventing severe disease outcomes. As the causative pathogen, severe acute respiratory syndrome coronavirus 2 (
Oyeniyi Diya, Juleen Gayed, Francine S. Lowry, Hua Ma, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Mark Cutler, Todd Belanger, David Cooper, Xia Xu, Robin Mogg, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin   +20 more
doaj   +1 more source

BNT162b2 Vaccine Booster and Covid-19 Mortality

New England Journal of Medicine, 2022
openaire   +3 more sources

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine, 2021
Skowronski, Danuta M., Serres, Gaston De, Vergnes, Jean-Noel   +2 more
openaire   +5 more sources

Sex differences in the long-term tolerability of BNT162b2 in children and adolescents. [PDF]

Mol Cell Pediatr
Moor J, Grieshaber V, Toepfner N, Holzwarth S, Moor MB, Kublickiene K, Strumann C, Chao CM.   +7 more
europepmc   +1 more source

Cutaneous Lymphomas and Lymphoproliferative Disorders Associated With SARS-CoV-2 Vaccination: A Systematic Review. [PDF]

J Skin Cancer
Mussi M, Zengarini C, Corrà A, Brunetti T, Natale A, La Placa M, Piraccini BM, Guglielmo A, Pileri A.   +8 more
europepmc   +1 more source

Effectiveness of BNT162b2 Vaccine for Preventing COVID-19-Related Hospitalizations: A Test-Negative Case–Control Study

It is important to understand real-world BNT162b2 COVID-19 vaccine effectiveness (VE), especially among racial and ethnic minority groups. We performed a test-negative case-control study to measure BNT162b2 COVID-19 VE in the prevention of COVID-19 ...
Larry J. Anderson, Srinivas Rao Valluri, Caroline Ciric, Ben A. Lopman, Meg Taylor, Luis Salazar, Laura Puzniak, Chris Choi, Timothy L. Wiemken, Satoshi Kamidani, Evan J. Anderson, Amy Keane, Khalel De Castro, Anna Mitchell, John M. McLaughlin, Elizabeth Grace Taylor, Robin Hubler, Christina A. Rostad, Ashley Tippett, Olivia Reese, Theda Gibson   +20 more
core   +1 more source

Spatiotemporal distribution of SARS-CoV-2 vaccines and vaccine-related proteins in mice and humans. [PDF]

Sci Rep
Heinrich F, Lücke J, Zhang S, Sabihi M, Bernreuther C, Giersch K, Allweiss L, Hartmann K, Thies E, Lange P, Matschke J, Kühl AA, Mothes R, Radbruch H, Schröder AS, Heinemann A, Dandri M, Aepfelbacher M, Huber S, Giannou A, Glatzel M, Ondruschka B, Lütgehetmann M, Krasemann S.   +23 more
europepmc   +1 more source

Boosting capacity of a fourth dose BNT162b2 in cancer patients

European Journal of Cancer, 2023
Yana Debie, Peter A van Dam, Maria E Goossens, Marc Peeters, Timon Vandamme   +4 more
openaire   +3 more sources

Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. [PDF]

Virus Res
Valenzuela-Fuenzalida JJ, Valarezo LM, Silva V, Delgado F, Nazar-Izquierdo D, Bruna-Mejias A, Nova-Baeza P, Donoso MO, Amaro GO, Cifuentes-Suazo G, Moya MP, Gimeno JS, Konschake M, Loaiza-Giraldo JP.   +13 more
europepmc   +1 more source